Omeros
OMER
Market cap $199M

3.40 USD

-0.15

4.23%

At close Jun 13, 4:00 PM EDT

After hours

3.37

-0.03

0.88%

1 day

-4.23%

5 days

-10.53%

1 month

-23.25%

3 months

-56.74%

6 months

-55.44%

Year to date

-65.45%

1 year

-19.62%

5 years

-77.10%

10 years

-82.63%

About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Employees: 202

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

6% more funds holding

Funds holding: 128 [Q4 2024] → 136 (+8) [Q1 2025]

1.74% more ownership

Funds ownership: 45.83% [Q4 2024] → 47.57% (+1.74%) [Q1 2025]

14% less capital invested

Capital invested by funds: $262M [Q4 2024] → $227M (-$35.7M) [Q1 2025]

32% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 50

35% less call options, than puts

Call options by funds: $4.15M | Put options by funds: $6.34M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

165%

upside

Avg. target

$23

562%

upside

High target

$36

959%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	165%upside $9	Buy Initiated	10 Jun 2025
D. Boral Capital Jason Kolbert	959%upside $36	Buy Maintained	13 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about OMER published over the past 30 days

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation OMER with a Buy rating and a price forecast of $9.

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Zacks Investment Research

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros faces a significant cash burn, with only $52.5 million in cash as of March 2025. The company's cash runway is dangerously short, likely lasting only until late summer 2025, necessitating urgent financial action.

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation Reports First Quarter 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At March 31, 2025, we had $52.4 million of cash and short-term investments available for operations and debt servicing, a decrease.

Omeros Corporation Reports First Quarter 2025 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference.

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion.

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion.

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA de.

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

See News Rankings

Charts implemented using Lightweight Charts™